

## Media Release

Ahmedabad, India - Remus Pharmaceuticals Limited has entered into a Memorandum of Understanding to acquire a majority stake in Espee Biopharma & Finechem LLC (EBFL - Schaumburg, USA). The Board of Directors of the Company has approved the same at their meeting held today. The proposed acquisition shall be subject to the satisfactory completion of due diligence, execution of definitive agreement and compliance with statutory requirements, as applicable.

Founded in 2009, EBFL is a specialty solution provider to the pharmaceutical industry. EBFL distributes goods and provides services to innovators, multinational generic manufacturers, CROs, government bodies, and various other entities in more than 25 countries across 6 continents.

EBFL's average turnover for the last three years is more than US\$ 46 Million (Forty-Six Million US Dollars).

The proposed acquisition will help Remus to strengthen, leverage and to get additional market access through EBFL's network and existing business.

-END-

## **Remus Pharmaceuticals Limited**

**REGISTERED OFFICE:** 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

**USA OFFICE:**

5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. [remus@remuspharma.com](mailto:remus@remuspharma.com) | W. [www.remuspharma.com](http://www.remuspharma.com)

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536